Atezolizumab to be Involved in Increasing the Pathological Complete Response Rate in Triple-Negative Breast Cancer

Release Date: 27-Nov-2020

In the patients suffering from triple-negative breast cancer, the drug Atezolizumab is estimated to increase the overall pathological complete response by 10%. The drug used in the respective clinical research study was also able to turn PD-L1 negative tumor positive in the patients who have been treated with immunotherapy. But the investigational drug was not found to be successful in improving the overall pathological complete response when other drugs i.e. carboplatin and nab-paclitaxel were added to it. The pathological complete response in the patients who received atezolizumab-containing regimen was found to be 86.9% whereas patients who received only chemotherapy, pCR was found to be 56.2% and patients with IC1 (immune checkpoint) introduction received pCR andndash; 44.0%.


The primary aim of the researchers enrolled in the respective study was to test the pathological complete response in the patients at baseline to assess sTILs, iTILs, and PD-L1 expression on ICs and tumor cells (TCs), and their dynamics and association with pCR. It was found that the level of sTILs and iTILs in the patients was disproportionate when received carboplatin and nab-paclitaxel. Majority of the patients enrolled in the respective study received a robust increase in the TILs.


It was concluded that there was an overall decrease in the PD-L1 positivity in the group that received chemotherapy. Therefore, the overall clinical research study came out to be statistically significant as well as meaningful when compared with other ongoing clinical trials. It is believed that the overall emergence of the clinical trial i.e. approval of the product by the regulatory body will completely transform the entire cancer therapeutics market.

Need custom market research solution? We can help you with that too.